Company · founded 2001
Orphagen Pharmaceuticals (United States)
San Diego, United States · orphagen.com
- Citations, last 5 years
- 12
- Works, last 5 years
- 5
- h-index
- 20
- Scientists listed
- 1
- Grants since 2016
- 6
Grants received
2024–2026 · research · R44
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells
Scott Mcnear Thacher · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
2024–2027 · research · R44
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells
Scott Mcnear Thacher · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2022 · research · R44
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer
Scott Mcnear Thacher · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer
Scott Mcnear Thacher · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2021 · research · R44
Translational feasibility of an oral, non-hormonal, male contraceptive pill
Paul D Crowe · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Translational feasibility of an oral, non-hormonal, male contraceptive pill
Paul D Crowe · Orphagen Pharmaceuticals (United States) · funded by National Institutes of Health
